Gilead Spends $455 Million for Rights to New Breast Cancer Drug in Asia

Hot off the heels of Gilead’s June approval for Troldelvy for metastatic triple-negative breast cancer (TNBC) drug in China, the company has agreed to a deal buying exclusive rights to sell the drug in Asia from the China-based Everest Medicines. This agreement gives Gilead global control of Troldelvy’s distribution. Gilead got the drug in its $21 billion acquisition of Immunomedics, which previously sold the rights to the drug to Everest.

According to , “Trodelvy is the cornerstone of our solid tumour portfolio. We look forward to rapidly advancing our development program in Asia and to realizing the clinical potential of Trodelvy across diverse tumour types.”

To read more, click here.

(Source: PharmaPhorum, August 16th, 2022)